Skip to main content
. 2005 Oct 11;93(8):876–883. doi: 10.1038/sj.bjc.6602797

Table 2. Pharmacokinetic results.

Patient Dose (mg m−2) Cycle Cmax (μg l−1) AUClast (ha μg l−1) T1/2λz (h) CL (observed) (l h−1) Vz (observed) (l)
 1 48 1inj2 1737 463 0.54 181 142
 2 48 1inj2 2724 848 0.51 94 69
    1inj8 2059 630 0.61 125 109
    2inj8 1629 498 0.57 158 131
 3 48 1inj2 2253 1143 0.61 83 72
    1inj8 1289 816 0.42 115 69
 4 65 1inj3 2074 566 0.20 190 55
 5 65 1inj2 4371 1498 0.45 64 41
    1inj8 4105 1312 0.73 74 78
 7 65 1inj2 2968 2510 0.82 74 88
    1inj8 2914 2068 0.65 89 84
 8 85 1inj2 2335 1809 0.39 79 45
    1inj8 3672 2375 0.60 60 52
    2inj8 2804 1619 0.74 88 94
 9 85 1inj2 1624 1151 0.71 133 136
10 85 1inj2 2057 2094 0.71 102 104
    1inj8 1354 1250 2.05 151 447
11 110 1inj2 3507 4016 0.62 46 41
12 110 1inj2 2750 2345 0.69 70 70
13 110 1inj2 3237 3842 0.55 83 66
    1inj8 3578 3796 0.62 84 75
14 145 1inj2 4851 4946 0.87 55 69
    1inj8 3922 4428 0.57 62 51
15 145 1inj2 2869 3471 0.89 92 119
16 145 1inj2 1217 2021 0.71 150 153
    1inj8 2080 2349 0.67 169 164
    2inj8 1342 1779 0.72 224 233
17 145 → 190 1inj2 4159 3389 0.68 64 63
    1inj8 3370 4467 0.62 63 57
18 145 → 190 1inj2 2474 1928 0.50 96 70
    1inj8 2274 2390 0.50 103 74
    3inj2 6517 7173 0.75 44 48
19 145 → 190 1inj2 2961 3683 0.79 66 75
    2inj1 4002 6451 0.77 49 54
20 145 → 190 1inj2 2774 3397 0.66 89 85
    1inj8 2066 2611 0.81 151 176
    2inj8 3341 5044 0.72 79 82
21 145 → 190 1inj2 2894 2621 1.36 100 196
    1inj8 2161 2178 2.38 142 488
22 145 → 190 1inj2 2795 2870 0.67 101 97
23 145 → 190 1inj2 3202 2465 1.15 72 119
24 145 → 190 1inj2 1177 1267 0.38 215 118
    1inj8 493 816 0.42 352 214
25 145 → 190 1inj2 4508 4094 0.49 55 39
    1inj8 4283 5360 0.58 56 46
27 145 → 190 1inj2 2625 1578 0.69 106 106

Cmax=maximum concentration; Tmax=time of maximum observed concentration, AUClast=area under the curve from time of dosing to the last measurable concentration; AUCinf=area under the curve from the time of dosing to infinity; t1/2λz=terminal half-life ln2/λz, where λz is the first-order rate constant associated with the terminal log-linear portion of the curve; MRTlast=mean residence time from the time of dosing to the last measurable concentration; Vz=volume of distribution based on the terminal phase dose/λz*AUCinf; CL=total body clearance.

a

Patient 6 and 26 – not evaluable for PK, samples not taken.